Holen Sie sich die Stockscreener-App
18.20
0.76%
-0.14
Handel nachbörslich:
18.12
-0.08
-0.44%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$18.34
Offen:
$18.3
24-Stunden-Volumen:
22.52M
Relative Volume:
1.92
Marktkapitalisierung:
$1.78B
Einnahmen:
$2.23B
Nettoeinkommen (Verlust:
$-248.39M
KGV:
-6.7658
EPS:
-2.69
Netto-Cashflow:
$-697.55M
1W Leistung:
-9.99%
1M Leistung:
+14.97%
6M Leistung:
-82.34%
1J Leistung:
-86.74%
1-Tages-Spanne:
$17.79
$18.65
1-Wochen-Bereich:
$17.57
$20.35
52-Wochen-Spanne:
$10.41
$138.81
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Firmenname
Sarepta Therapeutics Inc
Sektor
Branche
Telefon
617-274-4000
Adresse
215 FIRST STREET, CAMBRIDGE, MA
Vergleichen Sie SRPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
18.20 | 1.79B | 2.23B | -248.39M | -697.55M | -2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-29 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-07-29 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-07-29 | Bestätigt | H.C. Wainwright | Sell |
| 2025-07-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-07-29 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-07-28 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-07-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-07-24 | Eingeleitet | Citigroup | Sell |
| 2025-07-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-07-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-07-21 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-07-21 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | Herabstufung | Mizuho | Outperform → Neutral |
| 2025-07-21 | Herabstufung | Needham | Hold → Underperform |
| 2025-07-21 | Herabstufung | UBS | Buy → Neutral |
| 2025-07-18 | Herabstufung | Needham | Buy → Hold |
| 2025-06-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-06-17 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-06-16 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-06-16 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | Herabstufung | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2025-04-02 | Hochstufung | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-11-27 | Bestätigt | Needham | Buy |
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Sell |
| 2024-11-07 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-07-29 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-12-13 | Fortgesetzt | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-21 | Eingeleitet | Wedbush | Outperform |
| 2023-10-31 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-04 | Eingeleitet | Citigroup | Buy |
| 2023-03-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Bestätigt | BTIG Research | Buy |
| 2022-12-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Bestätigt | Needham | Buy |
| 2021-12-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-08-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-01-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-11 | Herabstufung | UBS | Buy → Neutral |
| 2021-01-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Eingeleitet | Mizuho | Buy |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-08-21 | Bestätigt | Needham | Buy |
| 2019-07-09 | Bestätigt | Morgan Stanley | Overweight |
| 2019-07-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-10-12 | Eingeleitet | Bernstein | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Bestätigt | RBC Capital Mkts | Outperform |
| 2018-09-14 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-09-06 | Eingeleitet | Credit Suisse | Outperform |
| 2018-08-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Bestätigt | Robert W. Baird | Outperform |
| 2018-06-20 | Bestätigt | Needham | Buy |
| 2018-06-19 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
What institutional flow reveals about Sarepta Therapeutics Inc.July 2025 Institutional & Growth Focused Entry Reports - Newser
Price-Driven Insight from (SRPT) for Rule-Based Strategy - news.stocktradersdaily.com
Will Sarepta Therapeutics Inc. benefit from macro trends2025 Earnings Surprises & Long-Term Investment Growth Plans - Newser
Has Sarepta Therapeutics Inc. formed a bullish divergence2025 Major Catalysts & High Yield Equity Trading Tips - Newser
(SRPT) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Sarepta Shares Dip 0.76% Despite $410M Volume Rank 236th as Debt Refinancing and Legal Scrutiny Weigh - AInvest
Sarepta Therapeutics announces $700 million convertible note exchange and private placement - Investing.com
How Sarepta Therapeutics Inc. (SRPT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
What Fibonacci levels say about Sarepta Therapeutics Inc. reboundWeekly Trade Recap & High Accuracy Investment Entry Signals - Newser
Is Sarepta Therapeutics Inc. reversing from oversold territoryJuly 2025 Decliners & Short-Term Trading Opportunity Alerts - Newser
Sarepta Therapeutics Completes Convertible Notes Exchange - TipRanks
SRPT Stock Alert: Investors with Large Losses Should - GlobeNewswire
SRPT Stock Alert: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Sarepta Therapeutics, Inc. Class Action - GlobeNewswire Inc.
(SRPT) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
(SRPT) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Trading the Move, Not the Narrative: (SRPT) Edition - news.stocktradersdaily.com
Avoiding Lag: Real-Time Signals in (SRPT) Movement - news.stocktradersdaily.com
The Technical Signals Behind (SRPT) That Institutions Follow - news.stocktradersdaily.com
Key resistance and support levels for Sarepta Therapeutics Inc.July 2025 Final Week & Technical Pattern Recognition Alerts - Newser
(SRPT) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
(SRPT) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Cell and gene therapies on correction course but not sinking - Yahoo Finance
How (SRPT) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Discipline and Rules-Based Execution in SRPT Response - news.stocktradersdaily.com
Real time social sentiment graph for Sarepta Therapeutics Inc.Trade Risk Assessment & Low Volatility Stock Suggestions - Newser
Precision Trading with Sarepta Therapeutics Inc. (SRPT) Risk Zones - news.stocktradersdaily.com
Sarepta Therapeutics Inc. stock outlook for YEARWeekly Earnings Recap & Technical Entry and Exit Alerts - Newser
What MACD and RSI say about Sarepta Therapeutics Inc.Trade Entry Summary & Detailed Earnings Play Strategies - Newser
Responsive Playbooks and the SRPT Inflection - news.stocktradersdaily.com
(SRPT) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Elanco Animal Health to Replace Sarepta Therapeutics in S&P MidCap 400 - MarketScreener
Healthcare Sector Rebalancing: Capitalizing on Index-Driven Momentum in Elanco and Sarepta - AInvest
Trading Systems Reacting to (SRPT) Volatility - news.stocktradersdaily.com
Strategic Index Reallocations: Analyzing the Impact of Elanco and Sarepta's S&P Index Moves on Healthcare and Biotech Exposure - AInvest
Will Sarepta Therapeutics Inc. stock recover after recent dropRate Hike & AI Powered Buy and Sell Recommendations - Newser
Behavioral Patterns of SRPT and Institutional Flows - news.stocktradersdaily.com
Technical Reactions to SRPT Trends in Macro Strategies - news.stocktradersdaily.com
Understanding Momentum Shifts in (SRPT) - news.stocktradersdaily.com
Earnings visualization tools for Sarepta Therapeutics Inc.July 2025 Setups & Technical Confirmation Trade Alerts - Newser
Understanding the Setup: (SRPT) and Scalable Risk - news.stocktradersdaily.com
Sarepta Therapeutics (NASDAQ:SRPT) Earns Sell Rating from HC Wainwright - Defense World
Investors in Sarepta Therapeutics, Inc. (SRPT): Protect Your RightsContact Levi & Korsinsky Before August 25, 2025 - Newsfile
Levi & Korsinsky Helps Retail Investors SueWallSt Over Alleged Fraud by Sarepta Therapeutics, Inc. - Stockhouse
Finanzdaten der Sarepta Therapeutics Inc-Aktie (SRPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.96%
1.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):